Passive immunotherapies based on the administration of exogenous antibodies targeting the two hallmarks in AD pathology, which are Aβ and tau protein, have given ambiguous results and minimal therapeutic benefit [123]. This evidence concerns the gene MAPT and Alzheimer disease.